Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes (ENTICHIR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02136589|
Recruitment Status : Completed
First Posted : May 13, 2014
Last Update Posted : May 13, 2014
PG-analogues induce hyperemia as one of side effects in addition to IOP reduction.
IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.
Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs.
Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.
|Condition or disease||Intervention/treatment||Phase|
|Hyperemia Intraocular Pressure||Drug: dicrofenac and travoprost||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
Drug: dicrofenac and travoprost
dicrofenac drop 3 times a day travoprost 0.005% once daily
- IOP reduction [ Time Frame: 1 day ]effect of NSAID on IOP reduction by travoprost